Introduction
There are two distinct pulmonary vascular consequences of hepatic disorders: hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) (1) . HPS is characterized by arterial hypoxemia caused by intrapulmonary vascular dilatations, whereas POPH is a pulmonary hypertension syndrome with vascular obstruction and increased resistance to pulmonary arterial flow due to varying degrees of pulmonary endothelial/smooth muscle proliferation, vasoconstriction and in-situ thrombosis. Both have serious implications for liver transplantation (LT) and reflect quite different Table 1 (1). It is important to review the liverlung pathophysiology that underlies the development of this syndrome as new understandings and potential therapeutic interventions are evolving. would have a lower estimated threshold of < 65 mmHg.
Background
As a result of factors that cause portal hypertension (with or without cirrhosis; adults or children), splanchnic and systemic vascular tone is impaired, resulting in a hyperdynamic circulatory state with increased cardiac output and decreased system vascular resistance (2) . In this setting, the pulmonary vascular bed experiences vascular dilatation changes 3 that range from the subtle (documented, but with no obvious clinical presentation) to the debilitating (severe arterial hypoxemia requiring supplemental oxygen). Such pulmonary vascular bed abnormalities can be of two distinct types: diffuse, microscopic precapillary and capillary dilatations, and discrete, macroscopic arteriovenous communications that may resemble classic pulmonary arteriovenous malformations (1) . The diffuse pattern is by far the most common. These vascular abnormalities may lead to ventilation-perfusion mismatch (excess perfusion for given ventilation), oxygen diffusion-perfusion limitation (oxygen molecules not totally traversing through deoxygenated blood due the size of the dilatations) and anatomic right to left shunts (vascular structures that bypass normal alveoli-capillary interface) ( Figure 1 ). The clinical presentation includes exertional dyspnea, clubbing, cyanosis, spider angiomas and worsening of dyspnea as a patient moves from the supine to standing position (platypnea) (1) . Chest radiograph abnormalities may be subtle in both patterns and mimic interstitial lung disease in the diffuse situation. Chest CT scanning can identify the discrete lesions that are most commonly seen in the periphery and lung bases.
There appears to be no gender, race or hepatic disease relationship with HPS (3). 
Arterial Hypoxemia
Screening for hypoxemia is commonly accomplished by finger pulse oximetry (4). (5). It is well-documented that up to 30% of HPS patients may have other reasons for hypoxemia that includes hepatic hydrothorax, interstitial lung disease and chronic obstructive lung disease due to smoking (1) . In such cases the use of lung perfusion scanning (see below) can help quantify the degree of hypoxemia due to HPS, since all other conditions mentioned will not be associated with brain uptake of radiolabeled albumen (see below). Such distinction may be important in deciding how hypoxemia may be affected by liver transplantation.
Imaging
The existence of pulmonary vascular dilatations can be determined using either contrast All-cause post-LT mortality has ranged from 5-67% at various post-LT times depending upon the series. Which patients are at highest risk for LT? Severity of hypoxemia (PaO 2 < 50 mm Hg) and increased brain uptake (> 30%) after lung perfusion scanning correlate with worse post-LT survival (11, 12, 14) . The role of hypoxemia in transplant hospitalization deaths, as well as post-hospitalization morbidity and mortality, is difficult to discern from the existing literature. However, biliary and vascular complications seem to predominate and conceivably could be related to tissue hypoxia, thus contributing to such complications (11, 16) .
. Long-term survivals following LT in HPS patients are encouraging. In the published Mayo Clinic experience of 61 HPS patients, 5-year survival of all patients was 23% if LT was not accomplished (n=37); 76% 5-year survival was noted for those who underwent LT (n=24) (Figure 3 ) (14) . Unpublished analysis of an additional 44 HPS patients seen at the Mayo Clinic since that publication (a total cohort of n=105 HPS patients followed up to 300 months; 23 additional patients who underwent transplant), has documented a 5-year post-LT survival of 80% versus 35% survival for those not undergoing LT (19). 10 Centers experienced in managing HPS patients have reported excellent post-LT survivals even in the setting of severe hypoxemia (PaO 2 < 50 mm Hg) (16), however, post-LT morbidity may be significant as mentioned earlier (16) . Finally, it is important to note that living-donor LT (with reduced hepatic mass) can result in total resolution of HPS and excellent survival (11, 16) . Tables: 1   Figures: 3 References: 20 CME Questions: 14
